Cardiac effects of standard-dose halofantrine therapy

American Journal of Tropical Medicine and Hygiene

Volumn 54, Issue 3, 1996, Pages 229-231

  Matson, Paul A ^a   Luby, Stephen P ^b   Redd, Stephen C ^c   Rolka, Henry R ^d   Meriwether, Rebecca A ^e  

^a Ambulatory Care ^*  (United States)

^b AGA KHAN UNIVERSITY   (Pakistan)

^c CENTERS FOR DIS CONTR AND PREV   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e Office of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; HALOFANTRINE;

ADOLESCENT; ADULT; ARRHYTHMOGENESIS; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; ELECTROCARDIOGRAPHY MONITORING; HEART VENTRICLE ARRHYTHMIA; HUMAN; LONG QT SYNDROME; MALARIA FALCIPARUM; ORAL DRUG ADMINISTRATION; PLASMODIUM FALCIPARUM; RISK BENEFIT ANALYSIS;

EID: 0029927368     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1996.54.229     Document Type: Article

References (18)

1. ter Kuile FO, Dolan G, Nosten F, Edstein MD, Luxemburger C, Phaipun L, Chongsuphajaisiddhi T, Webster HK, White NJ, 1993. Halofantrine versus mefloquine in the treatment of multidrug-resistant falciparum malaria. Lancet 341: 1044-1049.
2. Weinke T, Loscher T, Fleischer K, Kretschmer H, Pohle HD, Kohler B, Schluak T, Clemens R, Bock HL, 1992. The efficacy of halofantrine in the treatment of acute malaria in non-immune travelers. Am J Trop Med Hyg 47: 1-5.
3. Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, White NJ, 1993. Cardiac effects of antimalarial treatment with halofantrine. Lancet 341: 1054-1056.
4. Nothdurft HD, Clemens R, Bock HL, Loscher T, 1993. Halofantrine: a new substance for treatment of multidrug-resistant malaria. Clin Invest 71: 69-73.
5. Bryson HM, Goa KL, 1992. Halofantrine. Drugs 43: 236-258.
6. The Medical Letter, Inc., 1992. Drugs for Parasitic Infections. Med Lett Drugs Ther 34: 17-25.
7. Centers for Disease Control and Prevention, 1993. Malaria in Montagnard Refugees-North Carolina, 1992. MMWR Morb Mortal Wkly Rep 42: 180-183.
8. Shanks GD, Watt G, Edstein MD, Webster HK, Loesuttiviboon L, Wechgritaya S, 1992. Halofantrine given with food for falciparum malaria. Trans R Soc Trop Med Hyg 86: 233-234.
9. Milton KA, Edwards G, Ward SA, Orme MLE. Breckenridge AM, 1989. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol 28: 71-77.
10. Cowan JC, Yusoff K, Moore M, Amos PA, Gold AE, Bourke JP, Tansuphaswadikul S, Campbell RWF, 1988. Importance of lead selection in QT interval measurement. Am J Cardiol 61: 83-87.
11. Bazett HC, 1920. An analysis of the time-relations of electrocardiograms. Heart 7: 353-370.
12. Hashida K, Moss AJ, Schwartz PJ, 1992. QT prolongation and ventricular arrhythmias. Ann NY Acad Sci 664: 1-247.
13. Veemendaal JR, Parkinson AD, Kere N, Reickmann KH, Edstein MD, 1991. Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine. Eur J Clin Pharmacol 41: 161-164.
14. Karbwang J, Milton KA, Na Bangchang K, Ward SA, Edwards G, Bunna D, 1991. Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria. Br J Clin Pharmacol 31: 484-487.
15. Castot A, Rapoport P, Le Coz P, 1993. Prolonged QT interval with halofantrine (letter). Lancet 341: 1541-1542.
16. Monlun E, Fillet O, Cochard JF, Favarel Garrigues JC, Le Bras M, 1993. Prolonged QT interval with halofantrine (letter). Lancet 341: 1541-1542.
17. Schouten EG, Dekker JM, Meppelink P, Kok FJ, Vandenbroucke JP, Pool J. 1991. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 84: 1516-1523.
18. World Health Organization, 1993. Drug alert: halofantrine. Wkly Epidemiol Rec 37: 1-2.